E
75.87
-0.57 (-0.75%)
| 前收盘价格 | 76.44 |
| 收盘价格 | 76.62 |
| 成交量 | 5,346,320 |
| 平均成交量 (3个月) | 3,831,981 |
| 市值 | 44,543,279,104 |
| 市盈率 (P/E TTM) | 41.92 |
| 预期市盈率 (P/E Forward) | 26.45 |
| 价格/销量 (P/S) | 7.32 |
| 股市价格/股市净资产 (P/B) | 4.31 |
| 52周波幅 | |
| 利润日期 | 22 Apr 2026 |
| 营业毛利率 | 75.71% |
| 营业利益率 (TTM) | 29.01% |
| 稀释每股收益 (EPS TTM) | 2.42 |
| 季度收入增长率 (YOY) | 6.20% |
| 季度盈利增长率 (YOY) | 1.70% |
| 总债务/股东权益 (D/E MRQ) | 6.86% |
| 流动比率 (MRQ) | 4.45 |
| 营业现金流 (OCF TTM) | 876.20 M |
| 杠杆自由现金流 (LFCF TTM) | 1.45 B |
| 资产报酬率 (ROA TTM) | 8.42% |
| 股东权益报酬率 (ROE TTM) | 16.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Edwards Lifesciences Corporatio | 看涨 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | 5.0 |
| 内部交易活动 | -2.0 |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.30 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Mid Growth |
| 内部持股比例 | 0.91% |
| 机构持股比例 | 89.29% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 110.00 (Stifel, 44.99%) | 购买 |
| 中 | 100.00 (31.80%) | |
| 低 | 87.00 (Canaccord Genuity, 14.67%) | 保留 |
| 87.00 (Baird, 14.67%) | 保留 | |
| 平均值 | 97.71 (28.79%) | |
| 总计 | 10 购买, 4 保留 | |
| 平均价格@调整类型 | 82.62 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 11 Feb 2026 | 103.00 (35.76%) | 购买 | 79.33 |
| 05 Dec 2025 | 103.00 (35.76%) | 购买 | 86.19 | |
| Goldman Sachs | 11 Feb 2026 | 95.00 (25.21%) | 购买 | 79.33 |
| Piper Sandler | 11 Feb 2026 | 100.00 (31.80%) | 购买 | 79.33 |
| 20 Jan 2026 | 98.00 (29.17%) | 购买 | 83.46 | |
| Truist Securities | 11 Feb 2026 | 89.00 (17.31%) | 保留 | 79.33 |
| 05 Dec 2025 | 92.00 (21.26%) | 保留 | 86.19 | |
| Wells Fargo | 11 Feb 2026 | 100.00 (31.80%) | 购买 | 79.33 |
| 05 Dec 2025 | 96.00 (26.53%) | 购买 | 86.19 | |
| Stifel | 20 Jan 2026 | 110.00 (44.98%) | 购买 | 83.46 |
| 07 Jan 2026 | 105.00 (38.39%) | 购买 | 84.83 | |
| Barclays | 12 Jan 2026 | 104.00 (37.08%) | 购买 | 83.01 |
| 08 Dec 2025 | 103.00 (35.76%) | 购买 | 84.32 | |
| UBS | 12 Jan 2026 | 95.00 (25.21%) | 保留 | 83.01 |
| 05 Dec 2025 | 92.00 (21.26%) | 保留 | 86.19 | |
| TD Cowen | 09 Jan 2026 | 97.00 (27.85%) | 购买 | 85.13 |
| JP Morgan | 18 Dec 2025 | 100.00 (31.80%) | 购买 | 84.80 |
| Canaccord Genuity | 17 Dec 2025 | 87.00 (14.67%) | 保留 | 84.84 |
| 05 Dec 2025 | 89.00 (17.31%) | 保留 | 86.19 | |
| Baird | 16 Dec 2025 | 87.00 (14.67%) | 保留 | 85.32 |
| 05 Dec 2025 | 88.00 (15.99%) | 保留 | 86.19 | |
| Citigroup | 11 Dec 2025 | 101.00 (33.12%) | 购买 | 84.24 |
| RBC Capital | 05 Dec 2025 | 100.00 (31.80%) | 购买 | 86.19 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| LIPPIS DANIEL J. | 76.44 | 77.16 | 12,364 | 944,853 |
| ULLEM SCOTT B. | - | 75.87 | -199 | -15,098 |
| ZOVIGHIAN BERNARD J | 75.87 | 76.16 | -22,430 | -1,714,549 |
| 累积净数量 | -10,265 | |||
| 累积净值 ($) | -784,794 | |||
| 累积平均购买 ($) | 76.16 | |||
| 累积平均卖出 ($) | 76.50 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| LIPPIS DANIEL J. | 职员 | 17 Feb 2026 | 处理 (-) | 198 | 78.45 | 15,533 |
| ULLEM SCOTT B. | 职员 | 16 Feb 2026 | 处理 (-) | 199 | 75.87 | 15,098 |
| LIPPIS DANIEL J. | 职员 | 16 Feb 2026 | 处理 (-) | 258 | 75.87 | 19,574 |
| ZOVIGHIAN BERNARD J | 职员 | 13 Feb 2026 | 处理 (-) | 2,920 | 75.87 | 221,540 |
| ZOVIGHIAN BERNARD J | 职员 | 13 Feb 2026 | 获得 (+) | 2,920 | 75.87 | 221,540 |
| ZOVIGHIAN BERNARD J | 职员 | 12 Feb 2026 | 卖 (-) | 22,430 | 76.44 | 1,714,549 |
| ZOVIGHIAN BERNARD J | 职员 | 12 Feb 2026 | 执行期权 | 25,350 | - | - |
| LIPPIS DANIEL J. | 职员 | 12 Feb 2026 | 获得 (+) | 12,820 | 76.44 | 979,961 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合